BSX
Boston Scientific Corporation
Stock
$42.60−0.63 (−1.46%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.5B | $4.5B | $3.4B | $2.5B | $1.5B | $1.9B | $1.5B | $1.8B | $310M | $1.4B | $1.2B | $691M | $1.3B | $1.1B | $1.3B | $1.0B | $325M | $835M | $1.2B | $934M |
| Capital expenditures | $904M | $876M | $790M | $711M | $588M | $554M | $376M | $461M | $316M | $319M | $376M | $247M | $259M | $245M | $226M | $304M | $272M | $312M | $362M | $363M |
| Free cash flow | $3.6B | $3.7B | $2.6B | $1.8B | $938M | $1.3B | $1.1B | $1.4B | −$6.0M | $1.1B | $806M | $444M | $1.0B | $865M | $1.1B | $704M | $53M | $523M | $854M | $571M |
| Stock-based compensation | $320M | $299M | $266M | $233M | $220M | $194M | $170M | $157M | $140M | $127M | $116M | $107M | $103M | $105M | $108M | $128M | $150M | $144M | $138M | $122M |
| Buybacks | — | — | — | — | $0 | $0 | $535M | $0 | $0 | — | $0 | $0 | $125M | $500M | $600M | $492M | — | — | — | — |
| Dividends paid | — | — | $0 | $28M | $55M | $55M | $28M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | 17.3% | 18.2% | 15.8% | 12.6% | 7.4% | 11.1% | 11.4% | 12.8% | −0.1% | 12.2% | 8.9% | 5.5% | 13.5% | 12.2% | 14.5% | 9.2% | 0.7% | 6.4% | 10.6% | 6.8% |